| |
Sporadic cases
|
BRCA1 carriers
|
|---|
| | |
All familial cases
|
1135insA
|
1675delA
|
|
No of cases
|
100
|
30
|
10
|
20
|
|
Age at diagnosis: Median
|
59
|
49
|
52.5
|
47
|
|
range
|
39 – 80
|
39 – 80
|
41 – 80
|
39 – 65
|
|
FIGO stage
| | | | |
|
I – II
|
9 (9.0%)
|
8 (26.7%)
|
2 (20.0%)
|
6 (30.0%)
|
|
III
|
65 (65.0%)
|
14 (46.7%)
|
5 (50.0%)
|
9 (45.0%)
|
|
IV
|
26 (26.0%)
|
8 (26.7%)
|
3 (30.0%)
|
5 (25.0%)
|
|
Histology
| | | | |
|
Serous
|
82 (82.0%)
|
24 (80.0%)
|
7 (70.0%)
|
17 (85.0%)
|
|
Mixed
|
7 (7.0%)
|
2 (6.6%)
|
1 (10.0%)
|
1 (5.0%)
|
|
Endometroid
|
5 (5.0%)
|
3 (10.0%)
|
1 (10.0%)
|
2 (10.0%)
|
|
Unclassified
|
6 (6.0%)
|
1 (3.3%)
|
1 (10.0%)
|
0
|
|
Grade of differentiation
| | | | |
|
1
|
7 (7.0%)
|
0
|
0
|
0
|
|
2
|
26 (26.0%)
|
5 (16.6%)
|
1 (10.0%)
|
4 (20.0%)
|
|
3
|
67 (67.0%)
|
24 (80.0%)
|
9 (90.0%)
|
15 (75.0%)
|
|
Unknown
|
0
|
1 (3.3%)
|
0
|
1 (5.0%)
|
|
Survival >5 years
|
23 (23.0%)
|
10 (33.3%)
|
3 (30.0%)
|
7 (35.0%)
|
|
TP53 mutation status
|
72.0%
|
53.3%
|
50.0%
|
55.0%
|
- All tumors are epithelial adenocarcinomas
